What is Oblenio Bio?
Oblenio Bio operates at the intersection of advanced immunology and precision medicine, specializing in the development of next-generation immunotherapies for severe autoimmune conditions. The company's primary focus is the engineering of tri-specific T-cell engagers, a sophisticated modality designed to selectively deplete pathogenic immune cells while facilitating a long-term immune reset. By targeting the fundamental mechanisms of autoimmune disorders, Oblenio Bio aims to move beyond symptomatic management toward the realization of durable, drug-free remission for patients suffering from chronic, debilitating diseases. Its market position is defined by a commitment to transformative science that addresses significant unmet needs in the global healthcare sector.
How much funding has Oblenio Bio raised?
Oblenio Bio has raised a total of $62M across 1 funding round:
Series B
$62M
Series B (2026): $62M with participation from Aditum Bio, Deep Track Capital, Pfizer, and GV
Key Investors in Oblenio Bio
Aditum Bio
Aditum Bio is a biotech venture capital firm focused on rapidly translating scientific discoveries into innovative medicines.
Deep Track Capital
Deep Track Capital is an investment firm located in Greenwich, Connecticut, that specializes in the life sciences industry.
Pfizer
Pfizer is a biopharmaceutical company that researches, develops, manufactures, and markets medicines and vaccines across multiple therapeutic areas.
What's next for Oblenio Bio?
With the recent capital deployment, Oblenio Bio is poised to prioritize the clinical validation of its lead assets. The strategic focus will likely shift toward optimizing manufacturing processes for its tri-specific engagers and initiating early-stage human trials. Furthermore, the involvement of major industry players suggests a potential for future collaborative research or licensing agreements that could further validate the company's technological platform. As the firm continues to refine its therapeutic candidates, the focus will remain on achieving key clinical endpoints that demonstrate both safety and efficacy, ultimately aiming to disrupt the current standard of care for autoimmune patients worldwide.
See full Oblenio Bio company page
